Billionaire Steve Cohen’s Top 5 Small-Cap Stock Picks

2. BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX)

Number of Hedge Fund Holders: 26

The company develops treatments for inflammatory and contagious illnesses with key focus areas, including biochemistry, computer modeling, and biology. BioCryst also makes small-molecule treatments tested for hereditary angioedema, seasonal influenza, and uncomplicated influenza.

One of its latest milestones of the company is ORLADEYO’s approval as a treatment for hereditary angioedema in Japan. Torii Pharmaceutical Co. will be the BioCryst partner responsible for the commercialization and distribution of ORLADEYO in the Asian country. The company also announced that its prophylactic once-daily ORLADEY received the FDA’s approval for preventing hereditary angioedema attacks in pediatric patients above 12 years old.

Despite losing $46 million in Q3 2020, BCRX had healthy cash and cash equivalent profile at $148.5 million. It also received $325 million in funding from Athyrium Capital Management and Royalty Pharma plc (NASDAQ: RPRX). BioCryst’s commercialization of ORLADEYO in Japan is expected to deliver more value for investors, thus no surprise that it is on the list of Cohen’s favorite small-cap stocks.

A total of 26 hedge funds tracked by Insider Monkey were bullish BCRX at the end of the fourth quarter, up from 22 funds a quarter earlier.